In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 1 to 50 of 435

TitleTypeExpected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510Technology appraisal guidance
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]Technology appraisal guidanceTBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy [ID6354]Technology appraisal guidance
Advanced breast cancer: diagnosis and management (Partial update)NICE guidelineTBC
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575Technology appraisal guidanceTBC
Aggressive behaviour in people receiving NHS or social care: prevention and managementNICE guideline
AI software for electroencephalogram (EEG) interpretation in epilepsyHealth technology evaluationTBC
Alcohol Use Disorders (update)NICE guidelineTBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]Technology appraisal guidanceTBC
ALXN1840 for treating Wilson disease [ID6422]Technology appraisal guidanceTBC
Alzheimer's disease (early) - gantenerumab [ID6142]Technology appraisal guidanceTBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidanceTBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidanceTBC
Apraglutide for treating short bowel syndrome [ID6533]Technology appraisal guidanceTBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]Highly specialised technologyTBC
Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value AssessmentHealth technology evaluation
Artificial intelligence software to help detect and characterise colorectal polypsDiagnostics guidanceTBC
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Technology appraisal guidanceTBC
Asunercept for treating glioblastoma [1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Technology appraisal guidanceTBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Technology appraisal guidanceTBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Technology appraisal guidanceTBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Technology appraisal guidanceTBC
Atogepant for treating migraine [ID6615]Technology appraisal guidance
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Technology appraisal guidanceTBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]Technology appraisal guidance
Avelumab for previously treated platinum-resistant ovarian cancer ID1497Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]Technology appraisal guidanceTBC
Balloon cryoablation for Barrett's oesophagusInterventional procedures guidance
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]Technology appraisal guidanceTBC
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]Technology appraisal guidanceTBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]Technology appraisal guidance
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]Technology appraisal guidance
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Technology appraisal guidanceTBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]Technology appraisal guidance
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]Technology appraisal guidanceTBC
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]Technology appraisal guidanceTBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All